RxDoctor Payments Data

Ali Haq, MD

Internal Medicine · Henderson, NVNPI 1528597309

Payments from drug & device makers

$1,928in general payments, 2019–2025

Across 18 payments — averaging $107.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$337
  • GSK$239
  • Gilead$225
  • Teleflex LLC$219
  • Mallinckrodt Hospital Products Inc.$179
  • La Jolla Pharmaceutical Company$140
  • plus $588 from 6 others

What the payments were for

  • Food & beverage$1,928100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,928 in reported general payments places this provider in the 80th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$273,037
Medicare patients
460
Services billed
2,441

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban11$6,279
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen167$1,256
Albuterol Sulfate HfaAlbuterol Sulfate54$1,165
Ondansetron Hcl259$1,113
Lidocaine46$1,069
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav109$808
Pantoprazole Sodium161$517
Ciprofloxacin Hcl73$470
Tamsulosin Hcl22$173
ClopidogrelClopidogrel Bisulfate37$131
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim39$99
Amlodipine Besylate29$92
Atorvastatin Calcium29$87
Metoprolol Tartrate19$65
Metoprolol Succinate11$56

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$27$6,27911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →